BioSpace News Archive

Fosun Pharma USA Inc. (“Fosun Pharma USA”) announced today its abstract on ASTRIDE (NCT05468489), a phase 3 randomized, open-label study of serplulimab vs atezolizumab both in combination with chemotherapy (Carboplatin-Etoposide) in patients with extensive-stage small-cell lung cancer (ES-SCLC), has been accepted for presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2023 North America Conference on Lung Cancer (NACLC).

Pramand LLC announced the US commercial launch of the CraniSeal™ Dural Sealant System.

In a remarkable year of breakthroughs and strategic advancements, Gene Bio Medical, a promising venture in the Canadian biotechnology landscape, has solidified its position as a pioneer in healthcare innovation.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced the appointment of Francis Kim as Chief Regulatory and Quality Officer.

AIM ImmunoTech Inc. announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023.

Belhaven Biopharma proudly announces new Board of Director appointments and the initiation of a first in human clinical trial that positions the company as a novel alternative in the $2.5 billion U.S. epinephrine market.

Biovica International Continued sales growth and several commercial agreements signed.

Orexo AB, announces the New Drug Application for OX124 has been accepted for review by the US Food and Drug Administration.

Ethris GmbH announced that it has received approval from the United Kingdom Medicines and Healthcare products Regulatory Agency to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.

Harness Therapeutics announces that it has successfully raised an additional £4 million in funding from its existing investors, bringing the total invested to £17.6 million.